24.05.2019 • News

McDermott Wins Projects in Hungary and India

McDermott Wins Projects in Hungary and India
McDermott Wins Projects in Hungary and India

McDermott International’s Lummus Technology division has won two major contracts for propylene and polypropylene projects, in Europe and India.

For MOL Petrochemicals, the US chemical contractor will supply basic engineering, technology license, Novolen catalyst and Front End Engineering Design (FEED) for an Olefins Conversion Technology (OCT) plant to be built at Tiszaújvaros, Hungary.

The Hungarian facility will produce 100,000 t/y of polymer grade propylene from steam cracker and refinery feedstocks, utilizing Lummus' proprietary OCT and CDHydro Deisobutenizer. It also will also produce an isobutene-rich stream.

In India, McDermott will provide the license, basic engineering design and proprietary catalyst supply for a 475,000 t/y PP plant at Nagapattinam, Tamil Nau to be operated by. Chennai Petroleum Corporation Limited (CPCL), a group company of IndianOil.

The Indian unit, which will use Lummus' proprietary Novolen reactors and proprietary NHPcatalyst, will be able to produce a full range of leading polypropylene products for the Indian and regional markets, McDermott said.

The Chennai license is Lummus Technology’s fourth recent polypropylene technology award in India, and makes Novolen the leading for licensed polypropylene capacity in the country, with a total capacity of 3.1 million t/y said Leon de Bruyn, senior vice president of McDermott's Lummus Technology business.

McDermott did not name a start-up date or a contract value for either project.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.